MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
ADC Therapeutics SA (NYSE: ADCT) _(“ADC Therapeutics”)
Organization & Developments: ADC Therapeutics
Parents
ADC Therapeutics SA (NYSE: ADCT) _(“ADC Therapeutics”)
Children
* Antibody drug conjugates (ADCs)
*ADC employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells
*Biotech company that is focused on developing antibody-drug conjugates (ADCs) for the treatment of both solid and hematological cancers
2021: ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment
2022: ADC Therapeutics: Running Through A Stretch Of Bad Luck_ seekingalpha.com
2023: ADC Therapeutics: Navigating A Swirling Drain_ seekingalpha.com
2023: As Zynlonta sales disappoint, ADC Therapeutics cuts staff and preclinical programs
2024: ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation
2024: ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL_seekingalpha.com
2024: ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
2024: Limiting Concerns On ADC Therapeutics' Prospects
2025: ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%
2025: ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Jumps
Finance & Acquisitions: ADC Therapeutics
Key People: ADC Therapeutics